Filing Flows › Comparisons › EQ vs IMNM
Equillium vs Immunome: EQ and IMNM compared
Equillium is the larger company: $4.4M of revenue in its latest quarter (Q4 2024) against $4.0M for Immunome (Q2 2025). Immunome is growing faster (+70% against -52% a year earlier).
Where the money goes: EQ and IMNM
Equillium (EQ) · Q4 2024
Equillium, Q4 2024: revenue $4.4M (-52% year over year), operating margin -107.0%, net loss $5.8M, operating cash flow −$3.3M. The chart follows the revenue to costs, profit and cash.
Immunome (IMNM) · Q2 2025
Immunome, Q2 2025: revenue $4.0M (+70% year over year), net loss $43.4M, operating cash flow −$49.4M. The chart follows the revenue to costs, profit and cash.
| Equillium (EQ) | Immunome (IMNM) | |
|---|---|---|
| Latest quarter | Q4 2024 | Q2 2025 |
| Revenue | $4.4M | $4.0M |
| Revenue growth, Y/Y | -52% | +70% |
| Operating margin | -107.0% | n/m |
| Net earnings | −$5.8M | −$43.4M |
| Net margin | -131.9% | — |
| Operating cash flow | −$3.3M | −$49.4M |
Questions
Which is bigger, Equillium or Immunome?
Equillium is the larger company: $4.4M of revenue in its latest quarter (Q4 2024) against $4.0M for Immunome (Q2 2025).
Is Equillium or Immunome growing faster?
Immunome is growing faster (+70% against -52% a year earlier).
More: Equillium earnings · how Equillium makes money · Immunome earnings · how Immunome makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 27, 2025; 10-Q filed Aug 6, 2025). Fiscal quarters can end on different dates. Not investment advice.